Skip to content
Combined Shape Created with Sketch.
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

EyePoint Pharmaceuticals

02.04.19

EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiq

Source: EyePoint Pharmaceuticals

01.28.19

EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directors

Source: EyePoint Pharmaceuticals

01.03.19

EyePoint Pharmaceuticals to Launch Dexycu and Yutiq in First Quarter of 2019

Source: EyePoint Pharmaceuticals

12.17.18

EyePoint Pharmaceuticals Added to NASDAQ

Source: EyePoint Pharmaceuticals

11.27.18

EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary

Source: EyePoint Pharmaceuticals

11.12.18

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMS

Source: EyePoint Pharmaceuticals

10.29.18

EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAO

Source: EyePoint Pharmaceuticals

10.18.18

EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at the AAO 2018 Annual Meeting

Source: EyePoint Pharmaceuticals

10.15.18

EyePoint Pharmaceuticals Receives FDA Approval of Yutiq for Chronic Noninfectious Uveitis

Source: EyePoint Pharmaceuticals

10.01.18

EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants

Source: EyePoint Pharmaceuticals

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Glaucoma
  • Healthcare
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2019 Bryn Mawr Communications, LLC.

All Rights Reserved.